
    
      Randomized two arm, multi-site (three sites), open label pilot study conducted with
      laboratory evaluation and visits at entry, 4 weeks, 12 weeks, 24 weeks, 48 weeks and 96 weeks
      with laboratory evaluations and assessment if participants remain engaged in care.

      Participants will be randomly assigned with equal probability to one of two arms:

      Arm A: Same day antiretroviral therapy (ART) with bictegravir/emtricitabine/tenofovir
      alafenamide (BIC/F/TAF) + new diagnosis package with laboratory evaluations and social work
      referral.

      Arm B: Standard initiation of ART at the discretion of provider + new diagnosis package with
      laboratory evaluations and social work referral.
    
  